BACKGROUND: Elevated insulin-like growth factor-I (IGF-I) serum levels and phosphatase and tensin homolog (PTEN) loss are prostate cancer (PCa) risk factors that enhance androgen-responsive and castration-resistant PCa xenografts growth. METHODS: The impact of suppressed growth hormone (GH)/IGF-I levels on neoplastic initiation of PTEN-deficient prostate epithelia was assessed histologically and by epithelial-to-mesenchymal marker expression in Ghrhr D60G homozygous (lit/lit) and heterozygous (lit/ þ ) pbARR2-Cre, PTEN(fl/fl) (PTEN À / À ) mice. How suppressed GH/IGF-I levels impacted growth of PTEN À / À mouse-derived prostate cells (MPPK) was examined by growth and survival signaling of cells cultured in lit/ þ or lit/lit serum. RESULTS: Body weight, prostate weight and serum GH and IGF-I levels were reduced in lit/lit relative to lit/ þ PTEN À / À littermates. While the anterior lobes of lit/ þ PTEN À / À prostates consistently presented swollen, indicative of ductal blockage, the degree of prostatic dysplasia in 15-and 20-week-old lit/lit and lit/ þ PTEN À / À mice was indistinguishable as measured by normalized prostatic weight, tissue histology, or probasin, PSP94, E-cadherin, N-cadherin and vimentin expression. However, growth and AKT activation of MPPK cells was decreased when cultured in lit/lit serum as compared with lit/ þ serum and restored in lit/lit serum supplemented with IGF-I and, to a lesser extent, GH. CONCLUSIONS: These results suggest that initiation of prostate carcinogenesis by loss of PTEN is not influenced by germline variation of genes encoding signaling molecules in the GH/IGF-I axis, but suggests that these factors may affect the progression of dysplastic phenotype and supports previous studies, indicating that the GH/IGF milieu does impact the growth of PTEN-deficient dysplastic prostatic cells once transformed.
INTRODUCTION
The growth hormone and insulin-like growth factor-I (GH/IGF-I) axis is an important regulator of growth, survival and metastatic potential in a variety of malignancies and is strongly implicated in prostate cancer (PCa) etiology and risk. [1] [2] [3] [4] Perturbations in intrinsic expression of IGF axis components by tumor cells are implicated in susceptibility and progression of PCa. [5] [6] [7] [8] [9] [10] [11] [12] IGF-I receptor (IGF-1R) expression is elevated in metastatic PCa 13, 14 and castrationresistant disease progression is associated with increased expression of IGF-I and IGF-1R. 15 Furthermore, maintaining IGF-I responsiveness facilitates PCa survival and growth, and is achieved through androgen-modulated IGF-1R) expression. 14, 16, 17 IGF-I is a potent mitogen and antiapoptotic factor predominantly produced by the liver in response to GH signaling. 18 Ligand activation of IGF-1R results in the activation of multiple intracellular signaling pathways, including RAS/extracellular signalregulated kinases (ERKs) 1 and 2 and phosphatidylinositol-3 kinase (PI3K)/AKT that control the various IGF-mediated biological effects. 19 Activating mutations of PI3K have also been linked to PCa progression, 20 indicating the importance of deregulated PI3K signaling in PCa. The phosphatidylinositol phosphatase tumor suppressor, PTEN, is an important negative regulator of PI3K signaling. Homozygous loss of PTEN is a recurrent event in advanced PCa, 21 and among those patients who are not PTEN null, many exhibit loss of one PTEN allele. 22 We have previously reported that the GH/IGF-I axis is important for androgen-responsive growth, castration-resistant progression and growth of androgen receptor (AR)-negative, PTEN-deficient PCa xenografts in the lit/lit GH-releasing hormone-R loss-of-function murine host. 23 In addition, hemizygous PTEN loss, alone and in combination with the presence of TMPRSS2-ERG gene rearrangements, are reported in early stages of disease and to predict an increased risk of biochemical progression. 24, 25 This prediction is supported by the demonstration that a murine model for prostate-conditional PTEN loss is sufficient to induce development 26 and castrationresistant progression 27 of PCa. These results indicate that PTEN loss can hypersensitize cells to PI3K activation by factors such as GH and IGF-I. To test the hypothesis that dysplastic initiation of PTENdeficient prostate epithelial cells may be due to hypersensitivity to GH/IGF-mediated PI3K signaling, we assessed development of prostatic dysplasia in Ghrhr D60G (lit) Â pbARR2-Cre, PTEN(fl/fl) mice (PTEN À / À ). Our in vivo and in vitro results suggest that prostatic dysplasia induced by PTEN loss is not substantially affected by Ghrhr deficiency, but subsequent growth of dysplastic epithelia is impaired in hosts carrying germline deficiencies for GH and IGF-I expression, and may affect the progression of dysplastic phenotype in PCa.
MATERIALS AND METHODS
Ghrhr(lit/lit) and (lit/ þ ) pbARR2-Cre/PTEN(fl/fl) mouse characterization PTEN(fl/fl) C57BL/6J mice were obtained from T. Mak (Toronto, Canada) 28 pbARR2-Cre created in a C57BL/6 Â DBA2 hybrid mouse strain was obtained from P. Roy-Berman (Los Angeles, CA) 29 and Ghrhr D60G (lit/lit) C57BL/6J mice were from Jackson Laboratory (Bar Harbor, ME).
30 pbARR2-Cre, PTEN(fl/fl) mice (PTEN À / À ) generated, as described previously, 31 were crossed with lit/lit mice to produce lit/lit and lit/ þ PTEN À / À mice. This transgenic strain was genotyped to confirm the status of the Ghrhr allele mutation as described previously, 23 as well as confirming Cre recombinase and PTEN(fl/fl) status from tail clip DNA extracted using DirectPCR Lysis Reagent (Viagen Biotech, Los Angeles, CA, USA) and maintained by backcrossing. The extent of prostatic dysplasia was assessed in lit/lit and lit/ þ PTEN À / À mice at 15 and 20 weeks of age (10 mice per cohort). Prostate weights were determined after dissection and lancing of the lit/ þ anterior lobes to remove retained fluid. Prostate pathology was scored from formalin-fixed, paraffin-embedded, hematoxylin-and eosinstained specimens by a blinded pathologist (L Fazli). Probasin, PSP94, E-cadherin, N-cadherin and vimentin transcript levels were measured from total RNA prepared from flash-frozen total prostates by quantitative realtime polymerase chain reaction normalized to murine b-actin transcript for each specimen. Male mice were harvested in accordance with the guidelines of the Canadian Council on Animal Care and with appropriate institutional certification.
Cell lines
MPPK cells were established from prostate tissue from a 40-week-old pbARR2-Cre, PTEN(fl/fl) male mice as described 31 and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. LNCaP cells (courtesy of Dr LWK Chung, City of Hope Hospital, Los Angeles, CA, USA) were maintained in RPMI1640 þ 5% fetal bovine serum and DU145 cells purchased from American Type Culture Collection (Rockville, MD, USA) were maintained in Dulbecco's modified Eagle's medium þ 5% fetal bovine serum. Cells were cultured at 37 1C in a humidified 5% CO 2 atmosphere with media supplies purchased from Life Technologies (Burlington, Ontario, Canada).
In vitro cell proliferation assay MPPK cells were cultured in lit/lit and lit/ þ serum and in lit/lit serum supplemented with recombinant murine GH (R&D Systems, Minneapolis, MN, USA) or IGF-I (Calbiochem, San Diego, CA, USA) at the indicated concentrations. Proliferation was measured by pulse-labeling cells for 2 h with 10 mM bromodeoxyuridine (BrdU) after 46 h in culture. Denatured DNA in fixed cells was stained with a peroxidase-coupled anti-BrdUantibody and peroxidase substrate (tetramethylbenzidine) for 30 min and BrdU incorporation was measured by densitometry (OD 370 nm). Each assay was performed in triplicate.
Immunoblot analysis
Whole-cell protein lysates of LNCaP, DU145 and MPPK cells cultured in serum-free RPMI-1640 for 2 days±1 nM methyltrienolone, a synthetic androgen (R1881; Perkin-Elmer, Waltham MA, USA), were prepared in RIPA buffer (50 mM Tris-HCl, pH 7.2, 1% NP-40, 0.1% deoxycholate, 0.1% sodium dodecyl sulfate, 100 mM NaCl, 1 Â Roche complete protease inhibitor cocktail), subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose filters for immunoblotting with primary antibody (Ab): anti-AR and anti-vimentin rabbit polyclonal Ab (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-PTEN rabbit polyclonal Ab (Cell Signaling Technology, Danvers, MA, USA), anti-Ecadherin and anti-N-cadherin mouse monoclonal Ab (BD Biosciences, San Jose, CA, USA) and anti-b-actin mouse monoclonal Ab (Millipore Corporation, Billerica, MA, USA). Immunoreactive proteins were detected by enhanced chemiluminescence western blotting analysis system (Amersham Life Science, Arlington Heights, IL, USA), using horseradish peroxide-conjugated anti-rabbit or anti-mouse IgG Ab (Santa Cruz).
Whole-cell lysates of MPPK cells cultured in media supplemented with 1% lit/lit or 1% lit/ þ mouse serum for 2 days, or cultured 24 h in serumfree media, washed and then stimulated with media containing 1% lit/lit serum containing the indicated concentrations of recombinant murine GH or IGF-I for 20 min were immunoblotted with anti-vinculin mouse monoclonal Ab (Sigma Chemical, St Louis, MO, USA), anti-phospho-AKT (S473) rabbit polyclonal Ab, anti-AKT rabbit polyclonal Ab, anti-phospho-ERK1/2 (T185/Y187 and T202/Y204, respectively) rabbit polyclonal Ab, anti-ERK1/2 rabbit polyclonal Ab (all from Cell Signaling Technology) and detected by enhanced chemiluminescent as above.
Statistical analysis
Data were analyzed by analysis of variance and Mann-Whitney post hoc test, except for paired tests that were analyzed by Student's t-test. Levels of statistical significance were set at Po0.05. As predicted from the known effects of the Ghrhr D60G deficiency of lit/lit mice, the average serum GH level of lit/lit PTEN À / À mice at 15 and 20 weeks (0.2 and 0.6 ng ml À 1 , respectively) was on average B1/10th that measured in lit/ þ PTEN À / À mice (3.1 and 3.5 ng ml Figure 2d ). We next assessed whether PTEN À / À prostatic dysplasia was distinguishable when normalized for intrinsic differences in body size of lit/lit and lit/ þ mice, the prostate:body weight ratio was calculated for each animal and the average body weight-normalized prostate weight ratio was compared between the lit/lit and lit/ þ PTEN À / À cohorts ( Figure 2e ). Again, the body weight-normalized prostate weight ratio was indistinguishable between the PTEN À / À lit/lit and lit/ þ cohorts at 15 or 20 weeks; however, there was a significant increase in the prostate weight increase from 15 to 20 weeks for the lit/ þ cohort (60 mg) but not in the lit/lit cohort (30 mg).
RESULTS
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Furthermore, immunohistochemical analysis for Ki-67 staining of the dysplastic prostatic epithelia revealed that the mitotic activity between cohorts was indistinguishable (Supplementary Figure S1 ). Specimens were also assessed for PI3K activity as measured by phospho S473-Akt (pAKT) immunohistochemical staining intensity normalized to AR positivity as a marker of epithelial cell density (Supplementary Figure S2) . While we observed high constitutive pAKT levels, as expected, from prostatic PTEN knockout, there was no measurable difference in pAKT levels between cohorts. 26, 32 We conclude that elevated basal PI3K signaling and mitotic activity in PTEN-deficient prostates does not require normal physiologic IGF-I or GH levels.
In a parallel analysis, we compared prostatic pathology of 15-week-old lit/lit PTEN À / À mice with Ghrhr wild-type (wt) PTEN À / À mice (Supplementary Figure S3) . The overtly hypertrophic and swollen prostatic phenotype of the Ghrhr wt PTEN À / À mice was indistinguishable from that of age-matched lit/ þ PTEN À / À mice. The body weight-normalized total prostate weights of the Ghrhr wt PTEN À / À mice was 1.5 times greater than that of lit/lit PTEN À / À mice, but again this difference was Initiation of prostatic dysplasia in lit/lit mice K Takahara et al not seen when the Ghrhr wt PTEN À / À prostates were lanced to drain retained fluid. These results indicate that the lack of a difference between the lit/lit and lit/ þ prostate pathology was not due to a suppressed effect in response to Ghrhr D60G heterozygosity.
Assessment of epithelial and mesenchymal characteristics in dysplastic prostates of lit/lit and lit/ þ PTEN À / À mice To assess whether GH/IGF-I deficiency impacts prostatic epithelial differentiation in PTEN À / À mice, transcript levels of probasin ( Figure 3a ) and PSP94 ( Figure 3b) were measured by real-time reverse transcription-polymerase chain reaction analysis from total RNA of each mouse prostate collected at 15 and 20 weeks of age. Although the average mean expression of these markers in the lit/lit cohort at 20 weeks trended higher than the average of the other three cohorts, the expression of these prostatic epithelial markers was statistically indistinguishable between the lit/lit and lit/ þ cohorts at either time point or between time points for each cohort.
RAS/ERK pathway activation has been reported to promote epithelial-to-mesenchymal transition (EMT) in the prostates of PTEN À / À mice. 33 To assess whether the slightly lower average probasin and PSP94 expression in the 20-week lit/ þ cohort was associated with any evidence of EMT, real-time polymerase chain reaction was used to measure transcript levels of E-cadherin (Figure 3c ), vimentin ( Figure 3d ) and N-cadherin (Figure 3e ) from total RNA of each mouse prostate collected above. Normalized E-cadherin expression level was indistinguishable between the cohorts at either time point; however, there was an apparent increase in the relative expression of vimentin and N-cadherin transcripts from 15 to 20 weeks in both the lit/lit and lit/ þ cohorts. Although prostatic N-cadherin levels appeared to increase between 15 and 20 weeks in lit/ þ PTEN À / À mice compared with the lit/lit PTEN À / À mice, this difference was dominated by an apparent suppression of N-cadherin expression in the lit/ þ cohort that is likely a sampling artifact, as the mean N-cadherin expression level of the 15-week lit/lit and lit/ þ PTEN À / À cohorts was statistically indistinguishable. However, when protein expression for these markers was assessed from Figure 2 . Comparison of lit/lit and lit/ þ PTEN À / À male mouse body weight, serum growth hormone (GH) levels and serum insulin-like growth factor-1 (IGF-I) levels. Average ( ± s.e.m.) serum GH (a) and IGF-1 (b) levels, and body weight (c) and lanced prostate weight (d) of lit/lit (black bars) and lit/ þ (white bars) PTEN À / À mice at 15 and 20 weeks of age. (e) Prostate:body weight ratio was calculated for each animal and the average prostate/body weight ratio (±s.e.m.) was plotted for lit/lit (black bars) and lit/ þ (white bars) PTEN À / À mice. *Po0.05 by analysis of variance and Mann-Whitney post hoc test; n.s., no significant difference observed for indicated comparisons. PTEN, phosphatase and tensin homolog.
Initiation of prostatic dysplasia in lit/lit mice K Takahara et al prostatic lysates by immunoblotting normalized to b-actin levels, these trends for increased vimentin and N-cadherin expression in the 20-week cohorts were not confirmed (Supplementary Figure S4) . We conclude that although the consistently observed swelling of the anterior prostate lobes in the lit/ þ PTEN À / À mouse, indicative of blocked terminal prostatic ducts in these animals, suggests that dysplastic progression is delayed in the lit/lit hosts, morphologic and molecular marker expression changes indicate that genomic alterations that result in suppressed GH/IGF-I axis signaling do not affect initiation of prostatic dysplasia because of PTEN deletion.
Characterization of EMT marker expression in MPPK cells
We next assessed whether the previously established PTEN À / À mouse prostate cell line, MPPK, harbored any of the EMT characteristics implicated above by characterizing them for expression of prostatic epithelial and mesenchymal markers relative to that observed in well-characterized, androgen-responsive human prostate cancer cell line, LNCaP, and androgenindependent, AR-negative human prostate cancer cell line, DU145 (Figure 4a ). MPPK cells expressed AR and this expression was enhanced in the presence of R1881. Androgen responsiveness was confirmed by firefly luciferase reporter assay in MPPK cells transfected with pbARR2-Luc and stimulated 24 h with R1881 ( Figure 4b ). MPPK cells were also confirmed to be deficient for PTEN expression by comparison to expression in the PTEN wt DU145 cells and the PTEN-null LNCaP cells. MPPK cells exhibited robust E-cadherin expression, comparable to that observed in LNCaP cells. While MPPK cells expressed vimentin at low levels, comparable to that of LNCaP cells, relative to the robust expression in DU145 cells, they did express high levels of N-cadherin not observed in LNCaP and DU145 cells. This observation is consistent with the suggestion that PTEN À / À prostatic epithelial cells acquire intermediary mesenchymal characteristics while still in an intraepithelial neoplastic state and indicate that the MPPK cell line accurately reflects the phenotype of the dysplastic prostatic epithelia of PTEN À / À cells.
Growth of MPPK cells is suppressed in media supplemented with lit/lit serum To determine if growth characteristics of MPPK cells were sensitive to changes in GH/IGF-I levels, relative proliferation of MPPK cells cultured in basal media þ 1% lit/lit serum or 1% lit/ þ serum was examined by BrdU incorporation (Figure 4c ). Mitotic activity of MPPK cells cultured in 1% lit/ þ serum was significantly elevated (B40%) relative to that of cells cultured in 1% lit/lit serum. RAS/ mitogen-activated protein kinase and PI3K/AKT signaling have been implicated in transformation of PTEN À / À murine prostate epithelia. The effect of these culture conditions on steady-state RAS/mitogen-activated protein kinase and PI3K/AKT signaling was assessed by immunoblotting of MPPK, whole-cell lysates after culture in 1% lit/lit serum or 1% lit/ þ serum for 2 days for phospho-and total AKT and ERK, and vinculin (Figure 4d ). Densitometric quantification of phospho-to total AKT and Erk revealed that steady-state phospho-AKT levels were on average elevated fivefold, while phospho-ERK levels were not affected in cells cultured in lit/ þ serum vs those cultured in lit/lit serum. These observations are consistent with enhanced PI3K/AKT signaling in PTEN-deficient cells when cultured in the presence of GH-and IGF-I-containing serum.
Suppressed growth of MPPK cells in lit/lit serum can be rescued by the addition of GH or IGF-I To determine whether GH or IGF-I were sufficient to promote growth in lit/lit serum, MPPK cells were cultured in 1% lit/lit serum ± recombinant GH (0.1, 1 and 10 ng ml À 1 ) or recombinant IGF-I (5, 50 and 100 ng ml À 1 ) or 1% lit/ þ serum for 2 days (Figure 5a ). Relative mitotic activity was measured by BrdU incorporation and expressed relative to that of cells cultured without the addition of exogenous growth factors. The addition of GH to levels equal to or greater than that found in lit/ þ serum marginally affected MPPK cell proliferation, while supplementing lit/lit serum with IGF-I significantly enhanced MPPK proliferation at all concentrations tested. In contrast, proliferation of MPPK cells cultured in GH was significantly lower than that of cells grown in lit/ þ serum, while proliferation of cells grown in IGF-I were indistinguishable from that of cells grown in lit/ þ serum. These results suggest that suppressed IGF-I levels are primarily responsible for lower proliferation rate of MPPK cells in vitro.
To assess if intracellular signaling pathways were altered by growth factor supplementation of the lit/lit serum, lysates of MPPK cells cultured 24 h in serum-free media and stimulated with 1% lit/lit serum plus 0, 0.1 and 1 ng ml À 1 GH, or 0, 5 and 50 ng ml pathology. 14, 15, 19, 34 In addition, IGF-I expression and signaling or host GH and IGF-I levels are important regulators of PTEN-deficient human PCa cell xenograft growth. 23, 35 Using the probasin-SV40 T-Ag (TRAMP) prostate cancer animal model, we previously observed that tumor development was delayed when crossed into the lit/lit background, suggesting that risk of prostate carcinogenesis and progression may be influenced by germline variation of genes encoding signaling molecules in the GH/IGF-I axis. 34 In contrast, development of TRAMP tumors in hosts harboring targeted deletion of hepatic IGF-I did not show a delay in prostate carcinogenic kinetics, suggesting that differences in GH levels may impact TRAMP tumorigenic potential. 36 To help resolve how host GH and IGF levels might impact disease initiation, we assessed the impact of GH and IGF-I deficiency on prostate cancer initiation using a model more relevant to human disease that results in perturbation in the PI3K/ AKT pathway. A signature event impacting PI3K/AKT signaling in prostate cancer is hemi-and homozygous loss of the tumor suppressor, PTEN 22, 24 and prostate-specific deletion of the murine PTEN tumor suppressor gene leads to the development of prostate cancer. 26 To investigate the role of GH/IGF-I axis on the initiation of neoplastic progression of prostatic epithelial cells depleted for PTEN, we crossed lit/lit mice with PTEN À / À mice to produce lit/lit and lit/ þ PTEN À / À mice that were analyzed for the degree of prostatic pathology of lit/lit and lit/ þ PTEN À / À mice at 15 and 20 weeks of age. Prostates from lit/lit and lit/ þ PTEN À / À mice exhibited elevated pAKT levels and Ki-67-positive index in the AR-positive prostatic epithelium of both PTEN À / À cohorts is consistent with the loss of PTEN implicated to drive pathology in this animal model. 26, 32 While these prostates did not exhibit signs of true carcinogenic progression at the time points chosen, they did consistently display evidence of extensive prostatic dysplasia analogous to high-grade prostatic intraepithelial neoplasia. This lack of carcinogenic progression did not appear to be due to PTEN hemizygosity as Ghrhr wt PTEN À / À prostates revealed dysplasia indistinguishable from that of the lit/ þ PTEN À / À littermates. These observations are consistent with the kinetics of prostatic lesion formation in mice in which PTEN excision was induced at the beginning of puberty. 32 While this PTEN À / À phenotype was muted relative to that reported previously, 26 the consistent presentation of extensive intraepithelial neoplasia still allowed for comparison of how genetic variation for GH and IGF-I expression might affect initiation of prostatic intraepithelial neoplasia due to PTEN loss. The most obvious difference in prostate pathology between the lit/lit and lit/ þ PTEN À / À mice was the profound swelling of the anterior prostates of the lit/ þ littermates. Indeed, the increased body weight-normalized whole prostate weights of Ghrhr wt PTEN À / À mice may represent a subtle decrease in epithelial expansion in the GH/IGF-I-deficient hosts if the retained fluid is composed of shed cellular mass. However, once drained of retained fluid, the body mass-normalized prostatic weights were indistinguishable between the cohorts. In addition, microscopic evaluation revealed indistinguishable degrees of epithelial hyperplasia in this or any of the other prostatic lobes of these mice. These observations are consistent with the results from systemic PTEN þ / À mice in which knockout of IRS2 did not affect initiation of prostatic dysplasia but did delay lesion progression. 37 This lack of overt phenotypic difference in prostatic dysplastic initiation compelled us to examine molecular features of the lit/ þ and lit/lit PTEN À / À prostates. Recently, RAS/ERK activation was reported to cooperate with PTEN deficiency to promote EMT and metastatic behavior of prostatic progenitor cells. 33 We therefore assessed epithelial and mesenchymal characteristics of these cohorts. Murine prostatic epithelial differentiation marker expression (probasin, PSP94 and E-cadherin) were indistinguishable in lit/lit and lit/ þ PTEN À / À mice at the two time points analyzed here. The expression of mesenchymal markers, vimentin and N-cadherin, showed no indistinguishable difference between our lit/ þ and lit/lit PTEN À / À cohorts, but were readily detected in the prostates along with the epithelial marker, E-cadherin. While there was no apparent difference in presentation of EMT characteristics between the lit/lit and lit/ þ PTEN À / À mice, observations here of prostates with mixed epithelial and mesenchymal characteristics indicate that loss of PTEN expression alone is sufficient to initiate acquisition of mesenchymal characteristics and that these characteristics persist in cells derived from lymph node metastasis of prostate-derived PTEN À / À cells. Although prostatic dysplasia and acquisition of initial EMT characteristics induced by PTEN deficiency was not substantially affected by Ghrhr deficiency, these events may prime transformed cells for subsequent malignant progression by promoting expansion of cells with progenitor characteristics as described. 33 Ghrhr antagonists have been shown to suppress the growth of various human cancer lines as xenografts in immune-compromised mice, including inhibiting growth of PC3 and DU145 PCa xenografts. 38, 39 We have previously demonstrated that decreased circulating GH and IGF-I were significant contributors to suppressed growth of both androgen-responsive and castrationresistant PTEN-null PCa cells, 23 and that antisense oligonucleotide suppression of IGF-1R expression suppressed growth of these androgen-responsive and castration-resistant PTEN-null PCa cells. 35 These studies supported the contention that decreased IGF-I availability and signaling from IGF-1R to AKT was the primary missing growth stimulatory pathway for such cells in the lit/lit host. Consistent with these previous results, in this study, growth of MPPK cells was suppressed in media supplemented with lit/lit serum as compared with lit/ þ serum, and that restoration of suppressed growth of MPPK cells in lit/lit serum by the addition of IGF-I and, to a lesser extent, GH was correlated with increased steady-state activation of AKT. In contrast to the results from TRAMP crosses with lit/lit or hepatic IGF-I knockout mice that implicated a role for GH in driving TRAMP tumorigenesis, these in vitro experiments and our previous studies implicate circulating IGF-I as the predominant contributor to proliferation of PCa, and that this effect is mediated primarily through PI3K/AKT activation.
CONCLUSION
Our in vivo and in vitro experiments suggest that loss of PTEN may initiate prostatic epithelial dysplasia and acquisition of mesenchymal characteristics and that IGF-I may be an important factor in sustaining proliferation of these dysplastic cells. We therefore suggest that in early stages of PCa development, suppression of GH/IGF-I axis may delay invasive PCa progression. Such treatments might be best augmented by therapies targeting factors that regulate EMT, a process mechanistically linked with stem cell signatures in PCa cells 40 and increased resistance to apoptosis, diminished senescence, escape from immune surveillance and eventual resistance to therapy. 41 With the reports linking GH/IGF-I axis signaling to EMT and acquisition of stem-like properties, these results support continued effort to disrupt IGF axis signaling to control PCa progression.
